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Abstract 0 In this paper we report a novel technique of DNA-polymer
coating for gene transfer. A proprietary DNA polymer solution was
used for thin-layer coating on a chromic gut suture as a model study.
The coated sutures were characterized for physical properties such
as coating thickness, mass of the DNA deposited on the suture, surface
characteristics as determined by scanning electron microscopy, and
in vitro DNA release characteristics under simulated physiologic
conditions. The in vivo gene transfection using DNA-coated sutures
was demonstrated in rat skeletal muscle and in canine atrial
myocardium. A heat-stable human placental alkaline phosphatase
(AP) plasmid was used as a marker gene. Incisions of 1 to 1.5 cm
were made in the rat skeletal muscles or the canine atrial myocardium.
The sites were closed with either the DNA-coated sutures or control
sutures. Two weeks after the surgery, the tissue samples adjacent
to the suture lines were retrieved and analyzed for AP activity. The
DNA-coated sutures demonstrated a sustained release of the DNA
under in vitro conditions, with an ∼84% cumulative DNA release
occurring in 26 days. An agarose gel electrophoresis of the DNA
samples released from the suture demonstrated two bands, with the
lower band corresponding to the input DNA (supercoiled). It seems
that there was a partial transformation of the DNA from a supercoiled
to an open circular form due to the polymer coating. The tissue sites,
which received the DNA-coated sutures, demonstrated a significantly
higher AP activity compared with the tissue sites that received control
sutures. In the rat studies, the mean AP activity (square root of cpm/
µg protein) was 43.6 ± 3.3 vs 20.6 ± 2.1 (p ) 0.001) at the control
sites. Similarly, in the canine studies, the AP activity was 73.6 ± 7.4
Vs 21.6 ± 1.4 (p ) 0.0009) at the control sites. Thus, our studies
demonstrated a successful gene transfer using our DNA-polymer
coating technique. This technique could be useful for coating sutures
used in vascular and general surgery, and also for coating medical
devices, such as stents, catheters, or orthopedic devices, to achieve
a site-specific gene delivery.
Introduction
The concerns associated with viral vectors for gene
delivery,1-3 such as immunogenicity with the adenoviral
vectors or the risk of mutation with the retroviral vectors,
have led to a renewed interest in investigating nonviral
methods of gene delivery.4-9 A variety of nonviral methods
of gene delivery including liposomes,10,11 cationic lipid-
DNA complexes,12,13 and cationic polymer-DNA conden-
sates14-16 are under investigation. However, the important
limiting factor with the nonviral methods of gene delivery
is their comparative inefficiency to facilitate cellular uptake
of DNA and gene expression.17,18
Sustained-release drug delivery systems are currently
being investigated for DNA. These formulations include
microspheres, nanospheres, and polymer matrixes. The
DNA is either entrapped or dispersed into the polymer
matrix or adsorbed onto the surface. Biodegradable (poly-
esters, polyanhydrides) and nonbiodegradable polymers
(ethylene vinyl acetate copolymers), either synthetic or
natural (collagen, gelatin), have been investigated for
formulating sustained-release delivery systems.19 These
systems have demonstrated their efficacy for the sustained
delivery of proteins and peptides, which are comparatively
unstable in biological systems and require multiple dosing
to maintain a prolonged therapeutic effect.20-22
Sustained-release DNA delivery systems, in addition to
providing a controlled release of DNA, could also protect
the entrapped DNA from degradation due to nucleases.
Prolonged availability of the DNA released slowly from the
sustained-release DNA delivery system at the site of an
implant could increase the efficiency of cellular DNA
uptake. This prolonged availability could also lead to a
prolong duration of gene expression. In this paper, we have
described a novel DNA-polymer coating method for the
sustained delivery of DNA. A heat-stable human placental
alkaline phosphatase (AP) plasmid was used as a marker
gene. The goals of the studies were (1) to formulate a
sustained-release DNA coating; (2) to characterize the DNA
coating, study in vitro release characteristics of the DNA,
and characterize the DNA released from the coating; and
(3) to demonstrate in vivo gene expression in animal model
studies.
Materials and Methods
MaterialssA proprietary biodegradable DNA-polymer coating
preparation was obtained from Matrigen, Inc. (Ann Arbor, MI).
Trizama-HCl (Tris(hydroxymethyl)aminomethane) and ethylene-
diaminetetraacetic acid (EDTA) sodium salt were obtained from
Sigma Chemicals (St. Louis, MO). The following assay kits were
purchased: Alkaline Phosphatase Enzyme Kit (Phospho-Light)
from Tropiz, Inc. (Bedford, MA) and BCA Protein Assay Kit from
Pierce (Rockford, IL). Potassium phosphate, urea, and potassium
chloride were obtained from Mallinckrodt Specialty Chemical
Company (Paris, KY). All organic solvents and reagents were
either of HPLC grade or American Chemical Society analytical
grade reagents.
Plasmid DNA Sustained-Release PreparationsThe plas-
mid pcDNA3 (Invitrogen, Carlsbad, CA), containing a human
placental alkaline phosphatase gene under the control of human
cytomegalovirus (CMV) promoter, was propagated in Eschericia
coli and was isolated using a Qiagen Ultrapure column (Qiagen,
Inc., Chatswirth, CA). The structure and purity of the plasmid
preparation was assessed by agarose gel (0.8%) electrophoresis in
the presence of ethidium bromide to detect DNA bands. The
concentration of DNA in the plasmid preparation was determined
by ultraviolet (UV) spectrophotometric absorption at 260/280 nm
wavelengths. The plasmid DNA was incorporated into the Matri-
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gen coating system and applied to a 3-0 Chromic gut suture
(Ethicon, Inc. Somerville, NJ).
DNA-Polymer CoatingsTwo proprietary formulations of coating,
varying in DNA dose, were investigated. The high-dose formula-
tion contained 3.0 mg of DNA and the other formulation contained
1.0 mg of DNA per 70-cm length of suture. A multilayer solvent-
casting procedure was used for the DNA-polymer coating. The
coating was dried in air first for 3-4 h and then under desiccation
for 48 h.
Characterization of DNA SuturesThe DNA-coated sutures were
characterized for the mass weight increase, for surface character-
istics by scanning electron microscopy, and for in vitro release of
the DNA under physiologic conditions.
Scanning Electron MicroscopysA piece of coated and uncoated
suture was sputtered with carbon and was observed under a
scanning electron microscope (Amray, Model 1810, Bedford, MA)
at 150X magnification.
In Vitro Release of DNAsA DNA-coated suture (total length )
70 cm) was cut into pieces ∼7 cm in length. The pieces were
incubated with a Tris-EDTA buffer (pH 7.3, 50 mM, 5 mL) at 37
°C on a rotary shaker at 110 rpm. The buffer was replaced at
regular intervals of time. The experiment was performed in
triplicate. The samples were assayed for the DNA concentration
by high-pressure liquid chromatography (HPLC) as described next.
The samples were also analyzed by agarose gel electrophoresis
(0.8% agarose, 100 V, 40 min) to test the integrity of the released
DNA.
HPLC Analysis of DNAsThe HPLC system (Waters Company,
Milford, MA) consisted of two 501 pumps, an automated gradient
controller, a 712 WISP autosampler, a 481 Lambda-Max UV
detector, and a 756 Data module. A Nucleogen DEAE 4000-7
(Alltech, San Jose, CA) column was used for the DNA separations
using a mobile phase consisting of 5 M urea and 0.2 M potassium
phosphate adjusted to pH 6.5. The gradient was created with
potassium chloride (0.2-1.5 M).23 The flow rate was set at 2 mL/
min, and separations were monitored at 260 nm. A 100-µL sample
was injected for the purpose of DNA quantitation. Standard
curves of the input DNA were created for quantitation.
In Vivo Gene ExpressionsRat Skeletal Muscle Wound
ClosuresSix-week-old Sprague-Dawley rats (Charles River Labo-
ratories, Burlington, MA) were used for this study. Animals were
anesthetized with an intramuscular injection (0.001 mL/kg) of a
combination (4:3 v/v) of ketamine (100 mg/mL) and xyalazine (20
mg/mL). Under sterile conditions, the skin in the area of the
hindlimb was opened and 1-cm incisions were made with a scalpel
in the femoral extensor musculature. The wounds were closed
with either control or DNA-coated sutures (low-dose DNA suture,
260 µg of DNA per site). Two weeks after the surgery, the tissue
from the incision sites adjacent to the suture lines were retrieved
and stored frozen (-70 °C) until taken for the determination of
the AP activity.
Canine Atrial Myocardium Wound ClosuresThis experiment
was performed with a male mongrel dog weighing 30 kg. The
animal was anesthetized with an injection of sodium pentobarbital
(35 mg/kg), and anesthesia was maintained with halothane.
Under sterile conditions, the chest was opened and the heart was
exposed. A total of four incisions, each ∼1.5 cm, were made in
the right atrium of the heart. The wounds at two of the sites were
closed with the DNA-coated sutures (high-dose DNA suture, 780
µg per site) and at the other two sites with control sutures. The
DNA sites were ∼8-10 cm away from the control sites. After 2
weeks, the animal was euthanized with an overdose of pentobar-
bital, and the tissue samples from the atrium adjacent to the
suture linings were retrieved for analysis of AP activity.
Assay for Alkaline Phosphatase (AP) ActivitysThe frozen
samples were thawed, homogenized in TMNC buffer [50 mM Tris
pH 7.4, 5 mM MgCl2, 100 mM NaCl, and 4% CHAPS (3-[(3-
cholamidopropyl)-dimethylammonium]-1-propene sulfonate; 1 g
tissue/2.5 mL buffer] and centrifuged at 4000 × g for 15 min. The
supernatants were heated at 65 °C for 30 min to inactivate the
intrinsic cellular AP. A 20-µL aliquot of the supernatant was
mixed with a 100 µL of the assay solution and incubated at room
temperature for 5 min. The substrate (100 µL) was added to the
aforementioned mixture and again incubated at room temperature
for 20 min. The light output (cpm) was measured with a liquid
scintillation counter (Beckman LS-100, Fullerton, CA) on the 3H-
channel with the coincidence circuit on. The assay results were
normalized to the tissue protein concentration as determined by
the standard bicinchoninic acid (BCA) protein assay using bovine
serum albumin as a standard. The results were calculated as a
square root of the activity (cpm) per amount (µg) of protein.
Statistical AnalysissValues were expressed as mean (
standard error of mean (SEM). Comparisons were made using a
paired t-test as appropriate. A probability value (p) of <0.05 was
considered significant.
Results
The overall results demonstrated a successful DNA-
polymer coating methodology, sustained DNA release
characteristics, and in vivo gene expression in model
studies.
Characterization of DNA Coated SuturesThe coat-
ing resulted in a total deposition of 35 ( 2.5 (n ) 6) mg of
DNA polymer-coating preparation. Based on the amount
of DNA load in the coating formulation, the DNA coated
per entire suture length (70 cm) was 777.2 ( 0.05 µg. The
coating also resulted in a 30-µm increase in the suture
thickness. The scanning electron micrograph demonstrates
a uniform coating of the DNA-containing polymer (Figure
1), which is distinctly different from the surface of the
uncoated suture. The coating seems to have no effect on
the physical properties of the suture that would affect its
ability to function as a wound closure.
The in vitro release studies demonstrated sustained
DNA release characteristics with a 9.3% cumulative release
occurring during the first 24 h as a burst phase, followed
by a gradual elution with 84% cumulative release occurring
in 26 days (Figure 2). The coating was found to detach
from the suture after ∼3 weeks of the in vitro release study.
Thus, the DNA release from the coating seems to be due
to degradation of the polymer matrix. The DNA samples
released from the sutures demonstrated two bands of an
almost equal intensity on the agarose gel electrophoresis,
with a lower band corresponding to the original DNA
Figure 1sScanning electron micrograph of an uncoated and the DNA-polymer-
coated suture. The bar represents 280 µm.
Figure 2sIn vitro release of DNA from the DNA-coated suture under simulated
physiologic conditions.
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(supercoiled) (Figure 3). These data indicate that there was
a partial transformation of DNA from a supercoiled to an
open circular form. A similar transformation of the DNA
was observed in studies by Jong et al.24 when the DNA was
dispersed in the EVAc matrixes. As the solvent from the
DNA polymer coating solution evaporates, the DNA is
compressed in the polymer matrix. The physical forces
encountered during such entrapment could be responsible
for a transformation of DNA.25
In Vivo Gene ExpressionsEach incision site received
1/3 of the suture length (∼23 cm), which represents a total
DNA dose of 260 µg per site (or 7.6 µg/day) in rat studies
and 780 µg per site (or 22.8 µg/day) in dog studies. The
estimated dose was calculated from the DNA load in the
suture coatings and the in vitro DNA release characteris-
tics. There was no apparent inflammatory or untoward
tissue reactions at the incision site, indicating that the
coated sutures were well tolerated.
The tissue retrieved from the DNA suture site had
significantly higher AP activity compared with AP activity
in the tissue retrieved from the control suture sites. The
mean AP activity in the rat studies was 43.6 ( 3.3 in the
DNA delivery sites vs 20.6 ( 2.1 (p ) 0.001) at the control
sites (Figure 4). Similarly, in the canine studies, the mean
AP activity was 73.6 ( 7.4 in the DNA controlled-release
sites vs 21.6 ( 1.4 (p ) 0.0009) at the control sites. The
AP activity was represented as a square root of the activity
in cpm normalized to protein content (µg). The AP activity
in canine tissue samples was comparatively higher than
that in the rat tissues. This difference could reflect a dose
effect, because the sutures used in the dog studies had
three-fold higher DNA loading than the sutures used in
the rat studies.
Discussion
Our study demonstrated a novel DNA coating technique
for sustained DNA delivery. Successful in vivo gene
expression was demonstrated in rat skeletal muscles and
in canine myocardium. Sustained DNA delivery systems
offer many advantages over plasmid DNA solution admin-
istration in which the injected DNA could be rapidly
washed out from the site of administration or it could
undergo rapid degradation by nucleases. It is also known
that the injected DNA (e.g., intramuscular or subcutaneous
injections) drains rapidly into the lymphatics in certain
tissue,26,27 which could also significantly limit the avail-
ability of DNA. Sustained-release systems could prolong
the availability of the DNA, which could also lead to a
sustained duration of gene expression.
Other investigators have also demonstrated gene expres-
sion using sustained-release DNA delivery systems. Fang
et al.28 demonstrated gene expression in a rat bone fracture
model, which was packed with collagen sponge soaked in
a DNA solution for several hours before implantation.
Their studies demonstrated induction of new bone forma-
tion with therapeutic genes (PTH-34 and BMP-4). Col-
lagen is probably serving a twofold function in this experi-
ment: as a scaffold for the migrating cells and sustained
delivery of DNA. In another study, gene expression was
demonstrated on the serosal side of the intestine in rats
that received oral administration of polyanhydride micro-
spheres containing a marker DNA (â-galactosidase).29 The
bioadhesive characteristics of the polyanhydride micro-
spheres provided sustained release of DNA at localized
sites in the intestine. We have also demonstrated gene
expression in the rabbit iliac arterial wall following a local
infusion of PLGA nanospheres containing AP plasmid
DNA.30
Our coating technique could be useful for medical devices
such as stents, catheters, or orthopedic devices, to deliver
therapeutic genes locally at the site of implant. Stents
coated with a therapeutic gene could be useful for prevent-
ing restenosis. Myocardial gene expression has many
therapeutic applications, such as inducing angiogenesis in
the damaged myocardium, or expression of a gene that
could modulate pathways of electrical conductance to
control cardiac arrhythmias.39-44 In addition, coated su-
tures with an appropriate therapeutic gene (TGF-â) could
be used to enhance the wound healing process.45 Coating
of scaffolds with genes in tissue engineering is yet another
application of our coating technique.46
Conclusions
Our studies have demonstrated a novel method of DNA
coating for the sustained release of plasmid DNA. Our rat
and canine studies demonstrated in vivo reporter gene
expression using DNA-coated sutures. We conclude this
DNA delivery system offers the capability of incorporating
sustained-release DNA into virtually any implantable or
interventional device. Thus, surgical and invasive proce-
dures, as well as wound dressings, could be enhanced
through the coincorporation of the DNA delivery system
described in these studies. Therapeutic DNA administra-
tion could therefore be broadly used in a site-specific
manner with this technique.
Figure 3sResults of agarose gel electrophoresis of the DNA samples released
under in vitro conditions from the DNA-coated suture. (a) DNA ladder (75
base pairs to 23 Kilobase pairs; (b) input plasmid DNA, human placental
alkaline phosphatase, (c) 5-day controlled-release sample (2 µL); (d) 5-day
controlled-release sample (5 µL); (e) 8-day controlled-release sample (4 µL);
(f) 8-day controlled-release sample (10 µL).
Figure 4sAlkaline phosphatase activity in rat skeletal muscles at DNA-coated
suture sites (n ) 14) and control sites (n ) 5). The AP activity is represented
as a square root of the activity (cpm) normalized activity to amount (µg) of
protein. Data as mean ± sem.
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